Welcome To The Mannkind HUB On AGORACOM Edit this title from the Fast Facts Section
Picked this off yahoo from user hvacra250 but have not been able to confirm:
Conference Call to be held at 4:00 pm (EDT) today
VALENCIA, Calif.--(BUSINESS WIRE)--Aug. 14, 2013-- MannKind Corporation (Nasdaq:MNKD) today announced that it will hold a conference call at 4:00 pm (EDT) today to discuss preliminary results from Study 171 and Study 175, two Phase 3 clinical studies of AFREZZA® (insulin human [rDNA origin]) Inhalation Powder, an investigational, ultra rapid-acting mealtime insulin therapy administered using MannKind’s next-generation (Gen2) inhaler (also known as the Dreamboat™ inhaler).
conference call today at 4pmET 1-800-447-0521 or 1-847-413-3238. code 34077263
OOG
Please
login
to post a reply
